Suc-Leu-Tyr-AMC (Suc-LY-AMC)
博飞美科提供的所有产品仅用于科研等非医疗用途，非药品不可食用，不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。如您需要产品COA等资料，可至下方“质量控制”中下载
PA86089
PERFEMIKER
94367-20-1
C29H33N3O8
551.59
*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!
| 产品名称： |
Suc-Leu-Tyr-AMC,98% |
| 中文别名： |
N-琥珀酰基-亮氨酰-酪氨酸-7-胺基-4-甲基香豆素 |
| 英文名称： |
Suc-Leu-Tyr-AMC (Suc-LY-AMC) |
| 英文别名： |
L-Tyrosinamide,N-(3-carboxy-1-oxopropyl)-L-leucyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-;CALPAIN SUBSTRATE I;Suc-Leu-Tyr-AMC;CALPAIN SUBSTRATE II,FLUOROGENIC;N-SUCCINYL-LEU-TYR 4-METHYLCOUMARYL-7-AMIDE;N-SUCCINYL-LEU-TYR 7-AMIDO-4-METHYLCOUMARIN;succinyl-leucyl-tyrosyl-4-methyl-7-coumarylamide;SUCCINYL-LEU-TYR-AMC;SUC-LEU-TYR-7-AMINO-4-METHYLCOUMARIN;SUC-LY-AMC;N-Succinyl-Leu-Tyr-7-amido-4-methylcoumarin calpain substrate;N-(3-Carboxy-1-oxopropyl)-L-leucyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-L-tyrosinamide (ACI);L |
| 品牌： |
PERFEMIKER |
| CAS号： |
94367-20-1 |
| 分子式： |
C29H33N3O8 |
| 分子量： |
551.59 |
| 纯度： |
98% |
| 详细描述： |
博飞美科的Suc-Leu-Tyr-AMC,98%为抑制剂,产品稳定,定制速度快,极大地方便了广大科研客户的使用需求。产品包装为50mg。查询关键词:抑制剂，94367-20-1，Suc-Leu-Tyr-AMC,98%，Suc-Leu-Tyr-AMC (Suc-LY-AMC)，博飞美科，Perfemiker，上海，厂家直销。 |
沪公网安备31011402010658号 
C(%5bH%5d)(%5bH%5d)%5bC%40%40%5d(C(%5bH%5d)(%5bH%5d)%5bH%5d)(%5bC%40%5d(%5bH%5d)(%5bC%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O1)OC(C(%5bH%5d)(%5bH%5d)%5bH%5d)%3dO)O%5bH%5d)%5bC%40%40%5d1(%5bH%5d)%5bC%40%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bC%40%5d(%5bH%5d)(C1(%5bH%5d)%5bH%5d)O%5bC%40%40%5d1(%5bH%5d)%5bC%40%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bC%40%5d(%5bH%5d)(C1(%5bH%5d)%5bH%5d)O%5bC%40%5d1(%5bH%5d)C(C2C(%3dC3C(%3dC(C(%5bH%5d)(%5bH%5d)%5bH%5d)C(%3dC(%5bH%5d)C3%3dC(%5bH%5d)C%3d2C(%5bH%5d)(%5bH%5d)%5bC%40%40%5d1(%5bH%5d)%5bC%40%40%5d(%5bH%5d)(C(%5bC%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bH%5d)O%5bH%5d)%3dO)OC(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bC%40%40%5d1(%5bH%5d)C(%5bH%5d)(%5bH%5d)%5bC%40%5d(%5bH%5d)(%5bC%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O1)OC(C(%5bH%5d)(%5bH%5d)%5bH%5d)%3dO)O%5bC%40%5d1(%5bH%5d)C(%5bH%5d)(%5bH%5d)%5bC%40%5d(%5bH%5d)(%5bC%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O1)OC(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bH%5d)O%5bH%5d)O%5bH%5d)%3dO)O%5bH%5d)O%5bH%5d)
C%3d2)F)%3dO)%5bC%40H%5d1C1C%3dNC%3dCC%3d1)%3dO)(F)F)
%3dO)C(COC(CCCC%2fC%3dC%5cC%2fC%3dC%5cC%2fC%3dC%5cCCCCC)%3dO)COC(CCCC%2fC%3dC%5cC%2fC%3dC%5cC%2fC%3dC%5cCCCCC)%3dO)
O)O)C%2fC%3dC%5cCCC(%3dO)OC)